Y-mAbs Therapeutics (YMAB) to Release Quarterly Earnings on Friday

Y-mAbs Therapeutics (NASDAQ:YMAB) will be issuing its quarterly earnings data before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Y-mAbs Therapeutics has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The business had revenue of $22.80 million for the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter last year, the firm earned ($0.14) EPS. On average, analysts expect Y-mAbs Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Y-mAbs Therapeutics Stock Up 1.5 %

Y-mAbs Therapeutics stock opened at $15.10 on Wednesday. The company has a 50 day moving average price of $14.05 and a 200-day moving average price of $13.14. Y-mAbs Therapeutics has a fifty-two week low of $4.69 and a fifty-two week high of $20.90.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on YMAB shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Morgan Stanley reduced their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. BMO Capital Markets reduced their price objective on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Finally, Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.14.

Insider Activity

In other news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at $449,514. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at $449,514. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Thomas Gad sold 65,000 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $13.47, for a total value of $875,550.00. Following the sale, the insider now directly owns 97,681 shares in the company, valued at $1,315,763.07. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 100,000 shares of company stock valued at $1,338,100 over the last ninety days. 22.50% of the stock is currently owned by insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.